¹ Human Papillomavirus Infection Rate by

² Genotype and Vaccination Rates in

³ Canada: Canadian Health Measures

⁴ Survey 2009 to 2013

5 Authors

- 6 1. Yi-Sheng Chao, MD MPH PhD*
- 7 Independent researcher
- 8 Email: <u>chaoyisheng@post.harvard.edu</u>
- 9 *Corresponding author
- 10
- 11
- 12

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

13 Abstract

14 Background

- 15 An infection with certain HPV genotypes can lead to cancer or genital warts. HPV can be
- 16 detected with PCR-based tests, and some genotypes can be prevented by vaccines. However,
- 17 since the infection rates of various HPV genotypes have not been well reported, the present study
- 18 aims to provide this information.
- 19 Methods
- 20 The Canadian Health Measures Survey (CHMS) is an ongoing biannual national survey.
- 21 Between 2009 and 2011, it sampled a nationally representative sample of females aged 14 to 59
- 22 years to determine the infection rates of 46 HPV genotypes. Females aged 9 to 29 years and 9 to
- 23 59 years were asked whether they received HPV vaccines between 2009 to 2011 (cycle 2) and
- 24 2012 to 2013 (cycle 3), respectively. The reported infection rates and vaccination proportions
- 25 were weighted and adjusted for the survey design.
- 26 Results
- Among the estimated 10,592,968 females aged 14 to 59 years at cycle 2, the HPV genotypes
- 28 with the highest infection rates were 16, 62, 74, and 54, and the rates were 3.42% (95% CI =
- 29 1.67% to 5.17%), 2.14% (95% CI = 0.68% to 3.59%), 2.1% (95% CI = 0.51% to 3.69%), and
- 30 2.04% (95% CI = 0.38% to 3.7%), respectively. There were an estimated 6,569,100 and
- 31 11,603,752 females aged 9 to 29 and 9 to 59 years at cycles 2 and 3, respectively. The
- 32 proportions receiving a HPV vaccine were 13.55% (11.18% to 15.92%) and 12.3% (9.8% to
- 33 14.79%), respectively. The estimated numbers of females that received HPV vaccines were
- 34 890,197 and 1,427,000, respectively.
- 35 Conclusion
- 36 Canada is one of the few countries that conduct national surveys to determine HPV infection
- 37 rates by genotype, which are not limited to the surveillance of carcinogenic genotypes. Our study
- found discrepancies between the HPV genotypes whose infections were the most common, that
- 39 could be detected by PCR tests, that were carcinogenic, and that could be prevented by vaccines.
- 40 For example, 5 of the 7 genotypes (42, 54, 62, 66, and 74) with infection rates of more than 1%
- 41 cannot be detected by PCR tests and are not targeted by vaccines. HPV 51 is carcinogenic,
- 42 associated with genital warts, and can be detected by PCR tests, but it is not targeted by vaccines.
- 43 We recommend a better alignment of the genotypes targeted by HPV tests and vaccines with
- 44 those genotypes with the highest infection rates in Canada.
- 45 Key words
- 46 Human papillomavirus (HPV); Canadian Health Measures Survey (CHMS); genotype; vaccine;
- 47 polymerase chain reaction (PCR) test
- 48

49 Introduction

50 Human papillomavirus (HPV) infection is a major cause of cervical cancer and is related to other cancer or non-cancer lesions. [1, 2] The risk of cancer depends on the HPV genotypes. [1, 51 2] Figure 1, based on the findings of the International Agency for Research on Cancer (IARC), 52 53 identifies 12 HPV genotypes as carcinogenic (HPVs 16, 18, 31, 33, 45, 52, 58, 35, 39, 51, 56, 54 and 59) and 1 other as probably carcinogenic (HPV 68).[1, 2] Seven of the 13 genotypes (HPVs 55 16, 18, 31, 33, 45, 52, and 58) are associated with the occurrence of more than 90% of invasive 56 cervical cancer.[3] HPV 6 and 11 are associated with more than 90% of genital warts.[4] The prevalence of HPV infection differs by countries. Globally, in 2012, HPV infection was reported 57 58 to be prevalent among 10% of healthy women.[5] The infection rate ranges from 6.6% in Europe 59 to 22.9% in Africa, and HPV 16 infection is the most common among all HPV genotypes.[5] In 60 Canada, HPV is estimated to be the most common sexually transmitted disease, and more than 70% of sexually active Canadians are expected to have HPV infection in their lifetime.[6] It is 61 62 estimated that 6.2% of individuals with normal cervical cytology were infected with HPV 16 or 63 18.[7, 8] In terms of infection detection, polymerase chain reaction (PCR) based tests can detect 64 at least 13 high-risk genotypes (16, 18, 31, 33, 45, 52, 58, 35, 39, 51, 56, 59, and 68) and are 65 used for cervical cancer screening.[8] Those individuals identified with active HPV infection 66 may be referred to cervical exams for confirmation.[8] Currently, HPV tests have not been 67 included in routine cancer screening programs in Canada.[1]

68 Vaccination is an important strategy to prevent HPV infection[7, 9], and HPV vaccines 69 have been approved in Canada since 2006.[10] Between 2007 and 2010, public vaccination 70 programs began to be implemented for girls in various Canadian jurisdictions.[10] These public 71 vaccination programs have been expanded and now are available to other populations.[10] Several HPV genotypes are targeted by vaccines, especially 6, 11, 16, and 18.[10] Also, other 72 vaccines can be used to additionally target HPV 31, 33, 45, 52, and 58.[10] In Canada, the 73 74 vaccination rates found by various studies are estimated to be 69.62% and 18.66% for in-school 75 programs and community-based programs, respectively.[4] The vaccination rates for girls 76 eligible for HPV vaccination programs vary to a great extent between Canadian jurisdictions, 77 from 40% in the Northwest Territories to 91% in Newfoundland.[11]

78 HPV genotypes differ with respect to the development of various lesions, as to whether 79 they can be detected by available HPV tests, and as to whether they can be prevented by 80 vaccination. The infection rates of different HPV genotypes provide important information for 81 comparison with the assessment of potential disease burden, detectability via PCR tests, and 82 vaccine effectiveness. However, the estimates for HPV infection rates and vaccination rates are based on sporadic reports and diverse data sources. Such information is crucial for assessing the 83 84 effectiveness of public vaccination programs. Based on nationally representative Canadian data, 85 the present study reports on HPV infection rates by genotype and HPV vaccination rates.

86 Methods

87 The Canadian Health Measures Survey (CHMS) is an ongoing biannual national
88 biomonitoring survey that has interviewed Canadians since 2007.[12-16] Canadians who were

full-time military members, reserve residents, and institutional residents—less than 4% of the

90 population—were excluded from the sampling.[16, 17] More than 5,000 participants were

90 population—were excluded from the sampling.[10, 17] More than 5,000 participants were 91 interviewed in each of the 5 cycles that released data before Dec 2020.[12, 15-17] In addition to

92 face-to-face interviews, biological samples were obtained from the participants to determine

93 levels of various biomarkers or chemicals.[12-15, 18] By adjusting for the sampling strategies

94 and bootstrap weights, about 30 million Canadians were estimated for each of the 5 cycles, and 95 about half of them were female. [12, 14, 15, 17] Population characteristics and the numbers of

96 population by age were published elsewhere. [12, 14, 15, 19, 20]

97 In cycles 2 and 3, conducted between 2009 to 2011 and 2012 to 2013, respectively, 98

participants were asked whether they had received a HPV vaccine.[21] In cycle 2, 1,576 female

99 respondents aged 9 to 29 years were asked[21], and in cycle 3, 1,845 female respondents aged 9 100 to 59 years were asked.[21] The vaccination rates among eligible Canadians were reported in the 101 survey.

102 In cycle 2, 46 HPV genotypes were tested using urine samples (6, 11, 13, 16, 18, 26, 30, 103 31, 32, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 67, 68, 69, 70, 71, 72, 104 73, 74, 81, 82, 83, 84, 85, 86, 87, 89, 90, 91, and 97) (see Figure 1).[22] Samples were obtained 105 from 1,770 female respondents aged 14 to 59 years.[21] The infection rates among eligible 106 Canadians were reported in the survey.

107 Data analysis

108 To adjust for the survey design, bootstrap weights, sampling strata, regions, and personal 109 weights were used in the data analysis. [12-15, 23, 24] To protect the survey respondents' 110 confidentiality, the results were vetted based on specific rules, before they were released by the 111 Research Data Centre to researchers. [25] Only weighted statistics were released [25], and they 112 needed to meet a minimum sample size requirement. [26-30] To protect participant 113 confidentiality and prevent participants from being identified using the released data, Statistics 114 Canada did not allow the release of calculated proportions based on 10 or fewer unweighted 115 participants. At least one participant in each sampling site for each cycle was required.[12-15] In 116 total, to meet the minimum sample size requirement, roughly at least 100 respondents were 117 required for each cycle.[12-15] For these proportions that did not meet the requirement, 95% CIs 118 could not be released, and so the proportions provided in CHMS data dictionaries were used.[22] 119 All data analysis was conducted with R (v3.20)[51] and RStudio (v0.98.113).[52] 120 This secondary data analysis was approved by the ethics review committee at the Centre

121 Hospitalier de l'Université de Montréal. A consent to participate was not required for this 122 secondary data analysis.

Results 123

124 Cycle 2 (2009 to 2011) estimated 10.592,968 female Canadians aged 14 to 59 years. The

125 HPV genotypes with the highest infection rates were 16, 62, 74, and 54, and the rates were

126 3.42% (95% CI = 1.67% to 5.17%), 2.14% (95% CI = 0.68% to 3.59%), 2.1% (95% CI = 0.51%)

127 to 3.69%), and 2.04% (95% CI = 0.38% to 3.7%), respectively. Three HPV genotypes (66, 52,

128 and 42) were estimated to have infection rates between 1% and 2%. The other 39 HPV

129 genotypes were estimated to have infection rates less than 1%. The unweighted numbers of

130 participants infected with 28 HPV genotypes were fewer than those required by Statistics Canada,

131 and so 95% CIs of the infection rates of these HPV genotypes could not be released. Thus, the

132 infection rates of these genotypes were derived from data dictionaries (11, 13, 26, 30, 31, 32, 33, 133 35, 40, 43, 44, 45, 61, 68, 69, 70, 71, 72, 73, 82, 83, 85, 86, 87, 89, 90, 91, and 97). As a result,

95% CIs of the infection rates were not determined. No infection was identified with 7 HPV 134

135 genotypes (13, 26, 43, 69, 71, 85, and 97).

136 Vaccination rates

137 Cycle 2 (2009 to 2011) and cycle 3 (2012 to 2013) estimated 6,569,100 and 11,603,752 female Canadians aged 9 to 29 and 9 to 59 years, respectively. The proportions receiving an 138

139 HPV vaccine were 13.55% (95% CI = 11.18% to 15.92%) and 12.3% (95% CI = 9.8% to 14.79%), respectively. The numbers of females receiving HPV vaccines with respect to the 140 141 respective age ranges at cycles 2 and 3 were 890,197 and 1,427,000, respectively. 142 Infection rates, detection, carcinogenicity, and preventability 143 In Figure 1, HPV 16 is carcinogenic, [8] can be detected by PCR-based HPV tests, [31] 144 and can be prevented by HPV vaccines.[10] However, HPV 16 is not related to genital warts and 145 is not linked to the genotypes associated with genital warts. In contrast, 5 of the 7 HPV 146 genotypes (42, 54, 62, 66, and 74) with infection rates of more than 1% cannot be detected by 147 PCR-based tests (13 genotypes)[31] and are not targeted by HPV vaccines.[10]

148 There were 13 genotypes with infection rates less than 1% (HPVs 32, 35, 40, 44, 61, 72, 149 81, 83, 84, 87, 89, 90, and 91) that are not carcinogenic, cannot be detected by PCR tests, are not 150 associated with genital warts, and are not targeted by vaccines. HPVs 6 and 11 are associated 151 with genital warts and are targeted by vaccines, but they are not carcinogenic and cannot be detected by PCR tests. HPV 51 is carcinogenic, associated with genital warts, and can be 152 153 detected by PCR tests, but it is not targeted by vaccines. HPVs 35, 39, 56, and 59 are 154 carcinogenic and can be detected by PCR tests, but they are not associated with genital warts and 155 are not targeted by vaccines. HPVs 53, 68, 73, and 82 can be detected by specific PCR tests (19 156 genotypes), but they are not carcinogenic, are not associated with genital warts, and are not 157 targeted by vaccines. HPVs 18, 31, 33, 52, and 58 can be detected by PCR tests (13 genotypes), 158 are carcinogenic, and are targeted by vaccines (4, 9, 9, 9, and 9 genotypes, respectively), but they 159 not associated with genital warts. HPV 45 can be detected by PCR tests (13 genotypes), is 160 carcinogenic, and is associated with genital warts, and is targeted by specific vaccines (9) 161 genotypes). HPV 70 is associated with genital warts, but it is not carcinogenic, cannot be 162 detected by PCR tests, and is not targeted by vaccines. HPV 30 is possibly carcinogenic and is 163 associated with genital warts, but it is not carcinogenic and is not targeted by vaccines.

Among the HPV genotypes without any identified infection, HPVs 13 and 71 are not detected by PCR tests, are not carcinogenic, are not associated with genital warts, and are not targeted by vaccines. HPV 26 can be detected by specific PCR tests (19 genotypes), but is not carcinogenic, is not associated with genital warts, and is not targeted by vaccines. HPV 43 is associated with genital warts, but it is not detected by PCR tests, is not carcinogenic, and is not targeted by vaccines. HPVs 69, 85, and 97 are possibly carcinogenic, but they cannot be detected by PCR tests, are not associated with genital warts, and not targeted by vaccines.

171 Discussion

172 The present study reports the HPV infection rates by genotype determined at a time when 173 HPV vaccines were beginning to be used increasingly and were being promoted by public 174 programs in Canada. Such information is crucial for assessing the epidemiology of HPV 175 infection by genotype and the effectiveness of HPV vaccines. More importantly, we identified 176 discrepancies between the HPV genotypes whose infections are prevalent, that can be detected 177 by HPV tests, that are associated with cancer or genital warts, and that are targeted by vaccines. 178 Since the HPV genotypes considered carcinogenic may change over time, depending on available evidence, [32-35] the usefulness of commercially available PCR tests approved in 179 180 Canada—especially those reviewed by Health Technology Assessment (HTA)—may be 181 somewhat limited with respect to the genotypes chosen for HPV vaccines, and the choice of 182 targets for HPV infection surveillance.

183 Genotypes with high infection rates

184 HPV 16 is carcinogenic[8] and is the most common HPV infection in the world.[5] It also 185 is the genotype with the highest infection rates in Canada, a fact that has been recognized by 186 other researchers. [5, 36] The estimated infection rates of HPV 16 varies from 3.5% in healthy 187 women in North America^[5] to 4.7% of the normal cytology^[36] in Canada. The present study 188 estimates that between 2009 and 2011, 3.42% of Canadian females aged 14 to 59 years were 189 infected with HPV 16. However, studies disagree about the other HPV genotypes that have high 190 infection rates and the percentage of their infection rates. One study has estimated that HPVs 53 191 and 52 are the genotypes with the second and third highest infection rates in healthy women in 192 North America.[5] In this study, four out of the five HPV genotypes studied were carcinogenic 193 (HPVs 16, 18, 39, and 52), and the other one (HPV 53) was possibly carcinogenic.[5] In another 194 study that systematically reviewed and meta-analyzed trials or studies in Canada, HPVs 18 and 195 31 were the genotypes with the second and third highest infection rates.[36] In this study, 9 out 196 of the 10 HPV genotypes studied were carcinogenic, and the other one (HPV 66) was possibly 197 carcinogenic.[36] Results from previous studies may suggest that researchers' interests were 198 focused mostly on carcinogenic HPV genotypes, so infections from other HPV genotypes may 199 not have been as well studied as they should have been. The present study found that the 200 infections of several possibly carcinogenic genotypes (especially HPV 66) were more prevalent 201 than many carcinogenic HPV genotypes.

202 The infection rates of carcinogenic HPV genotypes were mostly lower than those rates estimated by synthesizing primary studies of various characteristics. For example, based on a 203 204 2014 meta-analysis, HPVs 18, 31, 66, 45, and 59 (ordered by infection rates) were the 205 carcinogenic genotypes estimated to be prevalent in more than 1% of normal cytology.[36] 206 However, in the nationally representative sample of females aged 14 to 59 years surveyed in the 207 CHMS, the infection rates of these genotypes were 0.51%, 0.45%, 1.83%, 0.32%, and 0.43%, 208 respectively. It is unclear whether the included smaller studies tended to obtain more high-risk 209 individuals or whether small-study effects have been well addressed.[37] The reasons for the 210 discrepancies in the estimated infection rates between studies were not clear. Thus, an extensive 211 review may be required of the population characteristics between studies and follow-ups of 212 infection trends in future cycles of the CHMS.

213 A lack of detection methods or preventive measures for certain HPV genotypes with the 214 highest infection rates does not mean these genotypes are not associated with adverse health 215 outcomes. Among the genotypes that could not be detected by PCR tests (12 to 18 genotypes) in 216 a health technology assessment (HTA) review, HPVs 42, 62, and 74 were associated with the 217 development of cervical lesions, cervical intraepithelial neoplasia.[38] The PCR tests reviewed 218 by the HTA were the tests that are used in primary screening, and many have been approved for 219 clinical use in Canada.[31] In Figure 1, HPVs 42 and 54 are associated with genital warts.[38] 220 We did not identify the major studies that have investigated the health impact of these genotypes 221 with high infection rates in Canada.

222 Detection and carcinogenicity

The HPV genotypes that PCR tests aim to detect include the 12 carcinogenic genotypes identified by the IARC classification updated in 2012.[31] HPVs 26, 53, 66, 68, 73, and 82 are the genotypes that can be detected using the PCR tests that can detect up to 18 genotypes.[31] In the IARC 2012 update, HPV 68 is considered probably carcinogenic, and HPVs 26, 53, 66, 73, and 82 are possibly carcinogenic.[33] HPVs 26 and 73 also are associated with common skin lesions.[38]

229 However, nine possibly carcinogenic genotypes (HPVs 5, 8, 30, 34, 67, 69, 70, 85, and 230 97) cannot be detected with the PCR tests (12 to 18 genotypes) reviewed by the HTA. In Figure 231 1, the HPV genotypes associated with genital warts cannot be detected by the PCR tests that can 232 identify 12 to 18 genotypes.[31] Moreover, vaccine-preventable HPV genotypes (6 and 11) 233 cannot be detected by these PCR tests. The role of these commercially available PCR tests may 234 be limited in detecting some possibly carcinogenic genotypes and those associated with genital 235 warts. With respect to policy evaluation, the genotypes that are not targeted by these PCR tests 236 should be considered when assessing HPV-related disease burden or the effectiveness of 237 preventive measures.

Moreover, one major limitation of many commercially available PCR tests is that only positive or negative results are reported, and the exact HPV genotypes detected are not reported.[31] If the HPV genotypes can be reported by PCR tests, this may help efforts to prevent further spreading of these genotypes.

242 Changes to the carcinogenicity classification

243 The 12 genotypes that can be detected by PCR tests match those classified carcinogenic 244 genotypes identified in the IARC 2012 update.[33] Figure 1 shows the additional genotypes that 245 can be identified by PCR tests that can detect 13, 14, or 18 genotypes that are probably or 246 possibly carcinogenic as defined by the IARC. Over time, changes have been made to the 247 carcinogenicity classifications of HPV genotypes. [35, 39] Although the present study found that 248 the infection rates of the possibly carcinogenic genotypes were not high, except for HPV 66, 249 their potential for carcinogenicity requires constant surveillance. Since some genotypes have 250 high infection rates, it may be easier to identify the patients infected with these genotypes for 251 follow-up. The CHMS can be used to assess related changes in the cancer burden attributable to 252 HPV infection, and which is preventable by vaccines.[40] The present study did not consider 253 several possibly carcinogenic genotypes (HPVs 5, 8, and 34) that may need follow-up in future 254 CHMS cycles.

255 Vaccination rates

256 The vaccination rates reported in the two CHMS cycles were based on two different age 257 ranges—9 to 29 and 9 to 59 years—and these rates decreased slightly over the two cycles from 258 13.55% to 12.3%, respectively. However, the absolute numbers of females receiving the 259 vaccines over the two CHMS cycles increased more than 60%. Vaccination programs in Canada 260 are expanding with public support. [9, 11] The target population also changed from school-age 261 girls in many provinces to other age groups and males.[41] Globally, between 2006 and 2019, 262 HPV vaccination indicated an increasing trend, and Canada was one of the countries with more 263 than 83% coverage among school-aged girls.[42] However, a considerable variability exists in 264 HPV vaccination rates across Canada.[42] In a recent estimate, the coverage rates of school-265 based HPV vaccination programs ranged from 59.4% in Ontario to 88.4% in Prince Edward 266 Island for girls in the 2016–2017 school year, compared to 52.5% in Ontario to 88.2% in 267 Newfoundland and Labrador for girls in the 2008–2009 school year.[43] Continuous efforts to 268 vaccinate younger generations will lead to better vaccination coverage.

It has been estimated that HPV vaccines can reduce cervical cancer and other HPVrelated cancers.[40] However, since most vaccines act against four or nine HPV genotypes,[10] many of the genotypes with high infection rates in this study were not targeted. Nevertheless, some evidence exists that cross-reactivity may be induced by HPV vaccines to act against nongenital HPVs.[44] At a population level, the herd immunity that protects unvaccinated

individuals also can be achieved when more individuals are vaccinated.[45]However, the exact

275 impact on infection rates of the genotypes not targeted by vaccines remains unclear. We expect 276 vaccination rates to continue increasing, and the influence of vaccines on the infection rates of

277 genotypes not targeted needs to be monitored.

278 Future research directions

The HPV genotypes with the highest infection rates provide opportunities for researchers to assess their health impact using human observational data. Carcinogenicity classification depends not only on animal data, but also on human trials or studies.[32] By following up individuals infected with HPV, it is possible to understand the impact of these HPV genotypes on health. The present study found that HPVs 54, 62, 74, and 86 are common and may be good candidates for long-term health studies.

Although these HPV genotypes are not directly targeted by vaccines, studies have shown that cross-reactivity with non-genital HPVs may be induced by vaccines.[44, 46] However, it is unclear whether cross-reactivity may be induced against the HPV genotypes with high infection rates. In the future, the impact of HPV vaccines on genotypes they target or do not target may be evaluated by using the data generated by large studies like the CHMS.

290 Over time, the use of HPV vaccines has been expanded to other age groups and males.[10] 291 Thus, in the future, it is important to collect data not only on other HPV genotypes, but also on 292 other population groups. The vaccinations against four or nine genotypes may cause spill-over 293 effects or herd immunity on other genotypes [44] or population groups. The infection rates and 294 vaccination history of other population groups may interact with the effectiveness of cervical 295 cancer prevention. Long-term follow-up may be needed. With the expansion of vaccination 296 programs, the cost effectiveness analysis of using HPV tests for primary cervical cancer 297 screening[31] may need to be updated.

IARC HPV Prevalence Surveys conducted outside of Canada have reported a clustering
 of particular HPV genotypes.[47] With this knowledge in mind, we are planning to study
 whether HPV clustering patterns may differ in Canada.

301 A study has found that the HPV PCR tests reviewed by a HTA did not have perfect 302 diagnostic test accuracy, i.e., 100% sensitivity and 100% specificity, for the detection of cervical 303 cancerous lesions or cervical intraepithelial neoplasia (CIN).[2] Most of the PCR tests reviewed 304 can detect 12 carcinogenic genotypes and 1 probably carcinogenic genotype, and report 305 positivity if any one of these genotypes is detected.[31] Figure 1[8] shows that several possible 306 carcinogenic genotypes and many genotypes associated with CIN[38] are not detected by 307 currently available commercial PCR tests. It is unclear to what degree the lack of detection of 308 possibly carcinogenic genotypes and those genotypes associated with CIN contributes to 309 imperfect diagnostic test accuracy.

Last, herd immunity disturbs HPV infection in a population, and thus protects those who are unvaccinated. In the future, the benefits of HPV vaccination are likely to be seen in the reduction of the incidence of both genital and non-genital cancer.[45] The assessment of the

313 magnitude of these benefits will depend on further data collection and analysis.

314 Limitations

The present study has the strength of a single data source, the CHMS, which reported vaccination status and which used consistent methods for HPV genotype quantification. Other studies may have depended on various sources to estimate infection rates, and so it is likely that many HPV genotypes were not tested and reported in the primary studies they reviewed.[36] However, the age ranges for vaccination status and HPV genotyping differed in the CHMS,

which leads to some difficulties in assessing the relationship between vaccination status andHPV infection by genotype.

Regarding a subgroup analysis, it is unlikely that Statistics Canada will grant its permission to release the infection rates or vaccination rates of subgroups that did not include large sample sizes. For example, it is unlikely that sufficient sample sizes exist for age-specific infection rates or city-wide infection rates. Moreover, the rates reported may not be applicable to subpopulations of specific characteristics. Only national rates are reported in this study.

The CHMS did not test for more than 46 HPV genotypes and several other genotypes associated with human diseases. For example, it did not test for HPVs 1, 2, and 4 that can cause common skin warts.[5, 38] It seems that the CHMS tested the HPV genotypes that were alpha types only.[5] Yet, it is unclear why these 46 genotypes were tested. We did not identify any

- 331 CHMS documents that explain why these genotypes were selected for testing. Based on our
- results, we think strategies for choosing genotypes for surveillance can be refined.

333 Conclusion

334 Canada is one of the few countries that conducts national surveys to determine HPV 335 infection rates by genotype, and it does not limit its surveillance to carcinogenic genotypes.[47] 336 The HPV genotypes with highest infection rates among females aged 14 to 59 years are HPVs 16, 337 62, 74, 54, 66, and 52 (3.42%, 2.14%, 2.1%, 2.04%, 1.83%, and 1.49%, respectively). With the 338 age ranges expanded from 9 to 29 years to 9 to 59 years between 2009 to 2011 and 2012 to 2013, 339 respectively, 890,197 and 1,427,000 females, respectively, were vaccinated against HPV in the 340 two time periods of the two CHMS cycles. Discrepancies exist between the HPV genotypes 341 whose infections are the most common, that can be detected by PCR tests, that are carcinogenic, 342 and that can be prevented by vaccines.

343 For example, HPV 16 is carcinogenic, can be detected by PCR tests, can be prevented by vaccines, and is the most common infection among all genotypes. However, five of the seven 344 345 genotypes (42, 54, 62, 66, and 74) with infection rates more than 1% cannot be detected by most 346 commercially available PCR tests [2, 31] and are not targeted by vaccines. HPVs 6 and 11, whose 347 infection rates were less than 1%, are associated with genital warts and can be prevented by 348 vaccines, but cannot be detected by most commercially available PCR tests.[31] HPV 51 is 349 carcinogenic, associated with genital warts, and can be detected by most commercially available 350 PCR tests, [31] but is not targeted by vaccines. Researchers are developing PCR tests to detect 351 more HPV genotypes[31] and are proposing methods to produce vaccines that can prevent HPV 352 of other genotypes. [48] Currently, some genotypes with the highest infection rates in Canada are 353 not targeted by PCR tests or vaccines. We recommend a better alignment of the genotypes 354 targeted by HPV tests and vaccines with those genotypes with the highest infection rates in

355 Canada.

356 Declaration

Required statement for the analysis of Statistics Canada data at the Research DataCentre

359 The analysis presented in this paper was conducted at the Quebec Interuniversity Centre

360 for Social Statistics (QICSS), which is part of the Canadian Research Data Centre Network

361 (CRDCN). The services and activities provided by the QICSS are made possible by the financial

- 362 or in-kind support of the Social Sciences and Humanities Research Council (SSHRC), the
- 363 Canadian Institutes of Health Research (CIHR), the Canada Foundation for Innovation (CFI),

364 Statistics Canada, the Fonds de recherche du Québec - Société et culture (FRQSC), the Fonds de

recherche du Québec - Santé (FRQS) and the Quebec universities. The views expressed in this paper are those of the authors, and are not necessarily those of the CRDCN or its partners[25].

- 367 Consent for publication
 - The consent for publication was not required for this secondary data analysis.
- 369 Acknowledgements
- 370 Not applicable.

371 Competing interests

YSC is employed by the Canadian Agency for Drugs and Technologies in Health. YSC
 conducted this study as an independent researcher out of academic curiosity without any material
 support. No external funding was received for this study. This study is not associated with any
 patents, products in development or marketed products

- 376 Authors' contribution
- 377 YSC conceptualized and designed this study, managed and analyzed data, and drafted the378 manuscript.

379 Availability of data and material

380 It is against the Statistics Act of Canada to release the CHMS data. The collection of the

381 CHMS data has been approved by the ethics committee within the governments of Canada. The

382 CHMS data have been de-identified and maintained by Statistics Canada. The data can be

accessed through the Research Data Centres administered by Statistics Canada. The details and

- eligibility for obtaining data access can be found online
 (https://www.statcan.gc.ca/eng/rdc/process).
- S85 (<u>nups://www.statcan.gc.c</u>
- 386 Funding
- 387 No specific funding for this study.
- 388

368

389 References

Chao Y-S, Clark M, Carson E, Weeks L, Moulton K, McFaul S, et al. HPV Testing for
 Primary Cervical Cancer Screening: A Health Technology Assessment. Canadian Agency for
 Drugs and Technologies in Health, Ottawa (ON); 2019.

Chao Y-S, Clark M, Ford C. HPV self-sampling for primary cervical cancer screening: a
 review of diagnostic test accuracy and clinical evidence. 2018.

395 3. Villain P, Gonzalez P, Almonte M, Franceschi S, Dillner J, Anttila A, et al. European
396 code against cancer 4th edition: infections and cancer. Cancer epidemiology. 2015;39:S120-S38.

3974.Bird Y, Obidiya O, Mahmood R, Nwankwo C, Moraros J. Human papillomavirus

vaccination uptake in Canada: a systematic review and meta-analysis. International journal ofpreventive medicine. 2017;8.

400 5. Crow JM. HPV: The global burden. Nature. 2012;488(7413):S2-S3.

401 6. Government of Canada. Human Papillomavirus (HPV) Ottawa, ON: Government of

402 Canada; 2020 [updated Feb 14, 2020; cited 2020 Dec 12, 2020]. Available from:

403 <u>https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-</u>
 404 <u>transmitted-infections/human-papillomavirus-hpv.html</u>

405 7. Bruni L, Barrionuevo-Rosas L, Albero G, Serrano B, Mena M, Gómez D, et al. Human
406 papillomavirus and related diseases report. L'Hospitalet de Llobregat: ICO Information Centre
407 on HPV and Cancer. 2014.

408 8. ICO/IARC HPV Information Centre. Canada. Barcelona, Spain: ICO/IARC HPV

409 Information Centre; 2019. Available from: <u>https://hpvcentre.net/statistics/reports/CAN_FS.pdf</u>.

410 9. Government of Canada. Human papillomavirus vaccine: Canadian Immunization Guide

411 Ottawa, ON: Government of Canada; 2020 [updated Feb 12, 2020; cited 2020 Dec 12].

412 Available from: <u>https://www.canada.ca/en/public-health/services/publications/healthy-</u>

413 <u>living/canadian-immunization-guide-part-4-active-vaccines/page-9-human-papillomavirus-</u>

414 <u>vaccine.html</u>.

415 10. Salvadori MI. Human papillomavirus vaccine for children and adolescents. Paediatrics &
416 child health. 2018;23(4):262-5.

417 11. Canadian Cancer Society. Toronto HPV vaccine rate trails provincial average Toronto,

418 ON: Canadian Cancer Society; 2016 [updated Sep 23, 2016; cited 2020 Dec 12]. Available from:
 419 <u>https://www.cancer.ca/en/about-us/for-media/media-releases/ontario/2016/sept/hpv-clinics-open-</u>
 420 for-boys/?region=on.

421 12. Chao Y-S, Wu C-J, Wu H-C, Chen W-C. Drug trends among non-institutionalized

422 Canadians and the impact of data collection changes in the Canadian Health Measures Survey

423 2007 to 2015. PloS one. 2019;14(4):e0214718-e. doi: 10.1371/journal.pone.0214718. PubMed 424 PMID: 30978234.

425 13. Chao YS, Wu HC, Wu CJ, Chen WC. Stages of Biological Development across Age: An
426 Analysis of Canadian Health Measure Survey 2007-2011. Front Public Health. 2018;5(2296-

427 2565 (Print)). doi: 10.3389/fpubh.2017.00355. eCollection 2017.

428 14. Chao Y-S, Wu H-C, Wu C-J, Chen W-C. Principal Component Approximation and

429 Interpretation in Health Survey and Biobank Data. Frontiers in Digital Humanities. 2018;5(11).

430 doi: 10.3389/fdigh.2018.00011.

431 15. Chao Y-S, Wu C-J, Wu H-C, Chen W-C. Trend analysis for national surveys:

432 Application to all variables from the Canadian Health Measures Survey cycle 1 to 4. PLOS ONE.

433 2018;13(8):e0200127. doi: 10.1371/journal.pone.0200127.

- 434 16. Giroux S. Canadian Health Measures Survey: sampling strategy overview. Health reports
- 435 / Statistics Canada, Canadian Centre for Health Information = Rapports sur la sante / Statistique
- 436 Canada, Centre canadien d'information sur la sante. 2007;18 Suppl:31-6.
- 437 17. Haines DA, Saravanabhavan G, Werry K, Khoury C. An overview of human
- 438 biomonitoring of environmental chemicals in the Canadian Health Measures Survey: 2007–2019.
- International Journal of Hygiene and Environmental Health. 2017;220(2, Part A):13-28. doi:
 <u>https://doi.org/10.1016/j.ijheh.2016.08.002</u>.
- 441 18. Tremblay MS, Connor Gorber S. Canadian health measures survey: brief overview. Can J
 442 Public Health. 2007;98(6):453-6. Epub 2008/12/02.
- 19. Carson V, Chaput J-P, Janssen I, Tremblay MS. Health associations with meeting new
- 444 24-hour movement guidelines for Canadian children and youth. Preventive Medicine. 2017;95:7445 13. doi: <u>http://dx.doi.org/10.1016/j.ypmed.2016.12.005</u>.
- 446 20. Statistics C. Population estimates on July 1st, by age and sex. Government of Canada.447 2016.
- 448 21. Statistics Canada. Canadian Health Measures Survey (CHMS) Data User Guide: Cycle 2.
 449 Ottawa, ON: Statistics Canada, 2013 April. Report No.
- 450 22. Statistics Canada. Canadian Health Measures Survey (CHMS) Data User Guide: Cycle 2
- 451 Ottawa, ON: Statistics Canada; 2013 [updated April 12, 2013; cited 2020 Dec 12]. Available 452 from: https://www23.statcan.gc.ca/imdb-bmdi/document/5071_D2_T1_V2-eng.htm.
- 453 23. Chao Y-S, Wu C-J. PD26 Principal Component Approximation: Canadian Health
- 454 Measures Survey. International Journal of Technology Assessment in Health Care.
- 455 2019;34(S1):138-9. Epub 01/03. doi: 10.1017/S026646231800301X.
- 456 24. Statistics Canada. Canadian Health Measures Survey (CHMS) Content summary for
- 457 cycles 1 to 8 In: Statistics Canada, editor. Ottawa, ON: Statistics Canada,; 2015.
- 458 25. The Quebec Inter-University Centre for Social Statistics (CIQSS). Statistics Canada Data
- 459 Montreal, QC: The Quebec Inter-University Centre for Social Statistics (CIQSS),; 2017 [cited
- 460 2017 Feb 1]. Available from: <u>https://www.ciqss.org/en/statistics-canada-data</u>.
- 461 26. Chao Y-S, Wu C-J, Wu H-C, Hsu H-T, Tsao L-C, Cheng Y-P, et al. Composite
 462 diagnostic criteria are problematic for linking potentially distinct populations: the case of frailty.
- 463 Scientific Reports. 2020;10(1):2601. doi: 10.1038/s41598-020-58782-1.
- 464 27. Chao Y-S, Wu C-J, Wu H-C, Hsu H-T, Tsao L-C, Cheng Y-P, et al. Using syndrome
- 465 mining with the Health and Retirement Study to identify the deadliest and least deadly frailty466 syndromes. Scientific reports. 2020;10(1):1-15.
- 28. Chao Y-S, Wu C-J, Wu H-C, Hsu H-T, Tsao L-C, Cheng Y-P, et al. Opportunities and
 challenges from leading trends in a biomonitoring project: Canadian Health Measures Survey
 2007 to 2017. Frontiers in Public Health. 2020;8:460.
- 470 29. Chao Y-S, Lin K-F, Wu C-J, Wu H-C, Hsu H-T, Tsao L-C, et al. Simulation study to
- 471 demonstrate biases created by diagnostic criteria of mental illnesses: major depressive episodes,
- 472 dysthymia, and manic episodes. BMJ Open. 2020;10(11):e037022. doi: 10.1136/bmjopen-2020-473 037022.
- 474 30. Chao Y-S, Wu C-J, Wu H-C, Hsu H-T, Tsao L-C, Cheng Y-P, et al. Opportunities and
- 475 Challenges From Leading Trends in a Biomonitoring Project: Canadian Health Measures Survey
 476 2007–2017. Frontiers in Public Health. 2020;8:460.
- 477 31. Chao YS, Clark M, Carson E, Weeks L, Moulton K, McFaul S, et al. HPV Testing for
- 478 Primary Cervical Cancer Screening: A Health Technology Assessment. Ottawa, ON: Canadian

- 479 Agency for Drugs and Technologies in Health; 2019. Available from:
- 480 <u>https://www.cadth.ca/sites/default/files/ou-tr/op0530-hpv-testing-for-pcc-report.pdf</u>.
- 481 32. World Health Organization, International Agency for Research on Cancer. Human
- 482 papillomaviruses. Geneva, Switzerland: World Health Organization; 2007.
- 483 33. International Agency for Research on Cancer. Agents classified by the IARC
- 484 monographs, volumes 1–128 Geneva, Switzerland: International Agency for Research on Cancer;
- 485 2020 [cited 2020 Dec 24]. Available from: <u>https://monographs.iarc.fr/list-of-classifications</u>.
- 486 34. Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human
 487 papillomavirus types: addressing the limits of epidemiology at the borderline. Infectious agents
 488 and cancer. 2009;4(1):8.
- 489 35. Muñoz N, Castellsagué X, de González AB, Gissmann L. Chapter 1: HPV in the etiology 490 of human cancer. Vaccine 24 (Suppl 3): S1–S10. 2006.
- 491 36. Bruni L, Barrionuevo-Rosas L, Albero G, Serrano B, Mena M, Gómez D, et al. Human
- 492 papillomavirus and related diseases report in Canada. Barcelona, Spain: L'Hospitalet de
- 493 Llobregat: ICO Information Centre on HPV and Cancer; 2019. Available from:
- 494 <u>https://hpvcentre.net/statistics/reports/CAN.pdf</u>.
- 495 37. Rücker G, Carpenter JR, Schwarzer G. Detecting and adjusting for small-study effects in
 496 meta-analysis. Biometrical Journal. 2011;53(2):351-68. doi:
- 497 <u>https://doi.org/10.1002/bimj.201000151</u>.
- 498 38. Burd EM. Human papillomavirus and cervical cancer. Clinical microbiology reviews.
 499 2003;16(1):1-17.
- 500 39. Meisal R, Rounge TB, Christiansen IK, Eieland AK, Worren MM, Molden TF, et al.
- 501 HPV genotyping of modified general primer-amplicons is more analytically sensitive and 502 specific by sequencing than by hybridization. PloS one. 2017;12(1):e0169074.
- 503 40. Volesky KD, El-Zein M, Franco EL, Brenner DR, Friedenreich CM, Ruan Y. Estimates
- 504 of the future burden of cancer attributable to infections in Canada. Preventive Medicine.
- 505 2019;122:118-27. doi: <u>https://doi.org/10.1016/j.ypmed.2019.04.006</u>.
- 506 41. Shapiro GK, Perez S, Rosberger Z. Including males in Canadian human papillomavirus 507 vaccination programs: a policy analysis. Canadian Medical Association Journal.
- 508 2016;188(12):881. doi: 10.1503/cmaj.150451.
- 509 42. Bruni L, Saura-Lázaro A, Montoliu A, Brotons M, Alemany L, Diallo MS, et al. HPV
- 510 vaccination introduction worldwide and WHO and UNICEF estimates of national HPV
- 511 immunization coverage 2010–2019. Preventive Medicine. 2021;144:106399.
- 512 43. Goyette A, Yen GP, Racovitan V, Bhangu P, Kothari S, Franco EL. Evolution of Public
- Health Human Papillomavirus Immunization Programs in Canada. Current Oncology.
 2021;28(1):991-1007.
- 515 44. Nakagawa M, Greenfield W, Moerman-Herzog A, Coleman HN. Cross-Reactivity,
- 516 Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-
- 517 Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV
- 518 Therapeutic Vaccines. Clin Vaccine Immunol. 2015;22(7):679-87. Epub 2015/05/06. doi:
- 519 10.1128/CVI.00149-15. PubMed PMID: 25947147.
- 520 45. Chaturvedi AK, Graubard BI, Broutian T, Xiao W, Pickard RKL, Kahle L, et al.
- 521 Prevalence of oral HPV infection in unvaccinated men and women in the United States, 2009-
- 522 2016. JAMA. 2019;322(10):977-9.

Faust H, Toft L, Sehr P, Müller M, Bonde J, Forslund O, et al. Human Papillomavirus
 neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination

525 with quadrivalent and bivalent HPV vaccines. Vaccine. 2016;34(13):1559-65.

526 47. Vaccarella S, Franceschi S, Snijders PJF, Herrero R, Meijer CJLM, Plummer M.

527 Concurrent Infection with Multiple Human Papillomavirus Types: Pooled Analysis of the IARC

528 HPV Prevalence Surveys. Cancer Epidemiology Biomarkers & amp; Prevention.

529 2010;19(2):503. doi: 10.1158/1055-9965.EPI-09-0983.

- 530 48. Wang D, Liu X, Wei M, Qian C, Song S, Chen J, et al. Rational design of a multi-valent
- human papillomavirus vaccine by capsomere-hybrid co-assembly of virus-like particles. Nature
 communications. 2020;11(1):1-15.
- 533
- 534
- 535
- 536



537 Figure 1. HPV genotypes by infection rates, HPV tests, carcinogenicity, association with genital warts, and HPV vaccines.

538

*In patients with epidermodysplasia vertuciformis. HPV = human papillomavirus; IARC = International Agency for Research on 539 540 Cancer; PCR = Polymerase chain reaction. Infection rates are obtained from a national representative sample of females aged 14 to 59 541 vears participating the Canadian Health Measures Survey. The HPV genotypes are listed in descending order of infection rates. The 542 HPV tests include the 13, 14, 15, and 19 HPV genotypes that are targeted by diagnostic tests using PCR.[1] The IARC classes are 543 obtained from the IARC database (https://monographs.iarc.fr/list-of-classifications).[8] The HPV genotypes associated with 544 Condyloma acuminata (genital warts) were obtained from a review.[38] The HPV vaccines include the 4 and 9 HPV genotypes that 545 these vaccines aim to prevent.[10] The same HPV genotypes are connected to each other across the categories.

546

